This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Evron, E. Articles by Sukumar, S. Search for Related Content PubMed PubMed Citation Articles by Evron, E. Articles by Sukumar, S.

Loss of Cyclin D2 Expression in the Majority of Breast Cancers Is Associated with Promoter Hypermethylation¹

Departments of Oncology, [E. E., D. K., D. M. L., S. S.], Surgery [C. B. U.], and Radiology [V. R.], Johns Hopkins University School of Medicine, Baltimore, Maryland 21231; Division of Medicine, Imperial College School of Medicine, London W12ONN, United Kingdom [B. N., L. B.]; Northwestern University Medical School, Chicago, Illinois 60611 [S. A. W.]; and Duke University Medical Center, Durham, North Carolina 27710 [J. M.]

Cyclin D2 is a member of the D-type cyclins, implicated in cell cycle regulation, differentiation, and malignant transformation. It was noted previously that cyclin D2 is not expressed in the majority of breast cancer cell lines, whereas abundant expression was detected in finite life span human mammary epithelial cells. By reverse transcription-PCR and Western blot analysis, we extended this finding to primary breast carcinomas and show that the majority of these tumors lack expression of cyclin D2 mRNA (18 of 24) and protein (10 of 13). In contrast, both luminal and myoepithelial subpopulations of normal breast tissues expressed cyclin D2. Hypermethylation of the CpG island in the promoter was detected by methylation-specific PCR in nearly half of the breast cancers (49 of 106) and was associated with silencing of cyclin D2 gene expression. Promoter hypermethylation was also detected in ductal carcinoma in situ, suggesting that loss of cyclin D2 expression is an early event in tumorigenesis. Our results suggest that loss of cyclin D2 expression is associated with the evolution of breast cancer.

This article has been cited by other articles:

				D. M. Euhus, D. Bu, S. Milchgrub, X.-J. Xie, A. Bian, A. M. Leitch, and C. M. Lewis DNA Methylation in Benign Breast Epithelium in Relation to Age and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1051 - 1059. [Abstract] [Full Text] [PDF]

				K. Narita, J. Chien, S. A. Mullany, J. Staub, X. Qian, W. L. Lingle, and V. Shridhar Loss of HSulf-1 Expression Enhances Autocrine Signaling Mediated by Amphiregulin in Breast Cancer J. Biol. Chem., May 11, 2007; 282(19): 14413 - 14420. [Abstract] [Full Text] [PDF]

				D. R. Yates, I. Rehman, M. F. Abbod, M. Meuth, S. S. Cross, D. A. Linkens, F. C. Hamdy, and J. W.F. Catto Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2046 - 2053. [Abstract] [Full Text] [PDF]

				M. Shamay, A. Krithivas, J. Zhang, and S. D. Hayward Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA PNAS, September 26, 2006; 103(39): 14554 - 14559. [Abstract] [Full Text] [PDF]

				M. O. Hoque, Q. Feng, P. Toure, A. Dem, C. W. Critchlow, S. E. Hawes, T. Wood, C. Jeronimo, E. Rosenbaum, J. Stern, et al. Detection of Aberrant Methylation of Four Genes in Plasma DNA for the Detection of Breast Cancer J. Clin. Oncol., September 10, 2006; 24(26): 4262 - 4269. [Abstract] [Full Text] [PDF]

				Q. C. Lau, E. Raja, M. Salto-Tellez, Q. Liu, K. Ito, M. Inoue, T. C. Putti, M. Loh, T. K. Ko, C. Huang, et al. RUNX3 Is Frequently Inactivated by Dual Mechanisms of Protein Mislocalization and Promoter Hypermethylation in Breast Cancer. Cancer Res., July 1, 2006; 66(13): 6512 - 6520. [Abstract] [Full Text] [PDF]

				A. P. Bracken, N. Dietrich, D. Pasini, K. H. Hansen, and K. Helin Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions Genes & Dev., May 1, 2006; 20(9): 1123 - 1136. [Abstract] [Full Text] [PDF]

				M. O. Hoque, E. Rosenbaum, W. H. Westra, M. Xing, P. Ladenson, M. A. Zeiger, D. Sidransky, and C. B. Umbricht Quantitative Assessment of Promoter Methylation Profiles in Thyroid Neoplasms J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4011 - 4018. [Abstract] [Full Text] [PDF]

				A. A. Melnikov, R. B. Gartenhaus, A. S. Levenson, N. A. Motchoulskaia, and V. V. Levenson (Chernokhvostov) MSRE-PCR for analysis of gene-specific DNA methylation Nucleic Acids Res., June 8, 2005; 33(10): e93 - e93. [Abstract] [Full Text] [PDF]

				U. Lehmann, I. Berg-Ribbe, L. U. Wingen, K. Brakensiek, T. Becker, J. Klempnauer, B. Schlegelberger, H. Kreipe, and P. Flemming Distinct Methylation Patterns of Benign and Malignant Liver Tumors Revealed by Quantitative Methylation Profiling Clin. Cancer Res., May 15, 2005; 11(10): 3654 - 3660. [Abstract] [Full Text] [PDF]

				J A Vendrell, I Bieche, C Desmetz, E Badia, S Tozlu, C Nguyen, J C Nicolas, R Lidereau, and P A Cohen Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines Endocr. Relat. Cancer, March 1, 2005; 12(1): 75 - 92. [Abstract] [Full Text] [PDF]

				W. Zhao, H. Soejima, K. Higashimoto, T. Nakagawachi, T. Urano, S. Kudo, S. Matsukura, S. Matsuo, K. Joh, and T. Mukai The Essential Role of Histone H3 Lys9 Di-Methylation and MeCP2 Binding in MGMT Silencing with Poor DNA Methylation of the Promoter CpG Island J. Biochem., March 1, 2005; 137(3): 431 - 440. [Abstract] [Full Text] [PDF]

				Q. Feng, A. Balasubramanian, S. E. Hawes, P. Toure, P. S. Sow, A. Dem, B. Dembele, C. W. Critchlow, L. Xi, H. Lu, et al. Detection of Hypermethylated Genes in Women with and Without Cervical Neoplasia J Natl Cancer Inst, February 16, 2005; 97(4): 273 - 282. [Abstract] [Full Text] [PDF]

				C. M. Lewis, L. R. Cler, D.-W. Bu, S. Zochbauer-Muller, S. Milchgrub, E. Z. Naftalis, A. M. Leitch, J. D. Minna, and D. M. Euhus Promoter Hypermethylation in Benign Breast Epithelium in Relation to Predicted Breast Cancer Risk Clin. Cancer Res., January 1, 2005; 11(1): 166 - 172. [Abstract] [Full Text] [PDF]

				P. Parrella, M. L. Poeta, A. P. Gallo, M. Prencipe, M. Scintu, A. Apicella, R. Rossiello, G. Liguoro, D. Seripa, C. Gravina, et al. Nonrandom Distribution of Aberrant Promoter Methylation of Cancer-Related Genes in Sporadic Breast Tumors Clin. Cancer Res., August 15, 2004; 10(16): 5349 - 5354. [Abstract] [Full Text] [PDF]

				M. J. Fackler, M. McVeigh, J. Mehrotra, M. A. Blum, J. Lange, A. Lapides, E. Garrett, P. Argani, and S. Sukumar Quantitative Multiplex Methylation-Specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast Cancer Cancer Res., July 1, 2004; 64(13): 4442 - 4452. [Abstract] [Full Text] [PDF]

				J. Mehrotra, M. Vali, M. McVeigh, S. L. Kominsky, M. J. Fackler, J. Lahti-Domenici, K. Polyak, N. Sacchi, E. Garrett-Mayer, P. Argani, et al. Very High Frequency of Hypermethylated Genes in Breast Cancer Metastasis to the Bone, Brain, and Lung Clin. Cancer Res., May 1, 2004; 10(9): 3104 - 3109. [Abstract] [Full Text] [PDF]

				J. Mehrotra, M. M. Ganpat, Y. Kanaan, M. J. Fackler, M. McVeigh, J. Lahti-Domenici, K. Polyak, P. Argani, T. Naab, E. Garrett, et al. Estrogen Receptor/Progesterone Receptor-Negative Breast Cancers of Young African-American Women Have a Higher Frequency of Methylation of Multiple Genes than Those of Caucasian Women1 Clin. Cancer Res., March 15, 2004; 10(6): 2052 - 2057. [Abstract] [Full Text] [PDF]

				L. Kopelovich, J. A. Crowell, and J. R. Fay The Epigenome as a Target for Cancer Chemoprevention J Natl Cancer Inst, December 3, 2003; 95(23): 1747 - 1757. [Abstract] [Full Text] [PDF]

				A. Padar, U. G. Sathyanarayana, M. Suzuki, R. Maruyama, J.-T. Hsieh, E. P. Frenkel, J. D. Minna, and A. F. Gazdar Inactivation of Cyclin D2 Gene in Prostate Cancers by Aberrant Promoter Methylation Clin. Cancer Res., October 15, 2003; 9(13): 4730 - 4734. [Abstract] [Full Text] [PDF]

				C. Qiu, L. Shan, M. Yu, and E. G. Snyderwine Deregulation of the Cyclin D1/Cdk4 Retinoblastoma Pathway in Rat Mammary Gland Carcinomas Induced by the Food-derived Carcinogen 2-Amino-1- methyl-6-phenylimidazo[4,5-b]pyridine Cancer Res., September 15, 2003; 63(18): 5674 - 5678. [Abstract] [Full Text] [PDF]

				H. Matsubayashi, N. Sato, N. Fukushima, C. J. Yeo, K. M. Walter, K. Brune, F. Sahin, R. H. Hruban, and M. Goggins Methylation of Cyclin D2 Is Observed Frequently in Pancreatic Cancer but Is Also an Age-related Phenomenon in Gastrointestinal Tissues Clin. Cancer Res., April 1, 2003; 9(4): 1446 - 1452. [Abstract] [Full Text] [PDF]

				B. Terris, E. Blaveri, T. Crnogorac-Jurcevic, M. Jones, E. Missiaglia, P. Ruszniewski, A. Sauvanet, and N. R. Lemoine Characterization of Gene Expression Profiles in Intraductal Papillary-Mucinous Tumors of the Pancreas Am. J. Pathol., May 1, 2002; 160(5): 1745 - 1754. [Abstract] [Full Text] [PDF]

				U. Lehmann, F. Langer, H. Feist, S. Glockner, B. Hasemeier, and H. Kreipe Quantitative Assessment of Promoter Hypermethylation during Breast Cancer Development Am. J. Pathol., February 1, 2002; 160(2): 605 - 612. [Abstract] [Full Text] [PDF]

				V. Shridhar, A. Sen, J. Chien, J. Staub, R. Avula, S. Kovats, J. Lee, J. Lillie, and D. I. Smith Identification of Underexpressed Genes in Early- and Late-Stage Primary Ovarian Tumors by Suppression Subtraction Hybridization Cancer Res., January 1, 2002; 62(1): 262 - 270. [Abstract] [Full Text] [PDF]

				B. Li, J. Goyal, S. Dhar, G. Dimri, E. Evron, S. Sukumar, D. E. Wazer, and V. Band CpG Methylation as a Basis for Breast Tumor-specific Loss of NES1/Kallikrein 10 Expression Cancer Res., November 1, 2001; 61(21): 8014 - 8021. [Abstract] [Full Text] [PDF]

				S. Dhar, R. Bhargava, M. Yunes, B. Li, J. Goyal, S. P. Naber, D. E. Wazer, and V. Band Analysis of Normal Epithelial Cell Specific-1 (NES1)/Kallikrein 10 mRNA Expression by in Situ Hybridization, a Novel Marker for Breast Cancer Clin. Cancer Res., November 1, 2001; 7(11): 3393 - 3398. [Abstract] [Full Text] [PDF]